nelarabine nda approved Oct 28, 2005 NDA number 021877 

The FDA medical review cites

Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I Study of 506U78 administered on a
consecutive 5-day schedule in children and adults with refractory hematologic
malignancies. J Clin Oncol 2005;23:3396-3382.

Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine ( compound 506U78)
in children and young adults with refractory T-cell malignancies: a report from the
Children's Oncology Group. J Clin Oncol 2005;23:3376-3403.


Patents:

US5424295:

Brink et al. Can. J. Biochem. 43(1): 1 15, 1965. *
Brink et al. Can. J. Biochem. 43(1): 1-15, 1965.
haskell, Ann. N.Y. Acad. Sci. 284:81 90, 1977. *
haskell, Ann. N.Y. Acad. Sci. 284:81-90, 1977.
Lagrauerend. et al. Tetrahedron 40(4): 709 713, 1984. *
Lagrauerend. et al. Tetrahedron 40(4): 709-713, 1984.
Martin et al. J. Pharm Sci 76(2): 180 184, 1987. *
Martin et al. J. Pharm Sci 76(2): 180-184, 1987.
Montgomery et al. J. Med. Chem. 12: 498 504, 1969. *
Montgomery et al. J. Med. Chem. 12: 498-504, 1969.
Reist et al. J. Org. Chem. 27: 3274 3279, 1962. *
Reist et al. J. Org. Chem. 27: 3274-3279, 1962.
S. Riva, et al., J. AM. Chem. Soc., 110, 584 9 (1988). *
S. Riva, et al., J. AM. Chem. Soc., 110, 584-9 (1988).
Smith et al., Cancer Treatment Reports 60(10): 1567 1584. *
Smith et al., Cancer Treatment Reports 60(10): 1567-1584. 

US5492897:

Andrew M. Yeager et al.; Autologous Bone Marrow Transplantation In Patients With Acute Nonlymphocytic Leukemia, Using Ex Vivo Marrow Treatment With 4 Hydroperoxycyclophosphamide; vol. 315; Jul. 17, 1986, No. 3; pp. 142 147. *
Andrew M. Yeager et al.; Autologous Bone Marrow Transplantation In Patients With Acute Nonlymphocytic Leukemia, Using Ex Vivo Marrow Treatment With 4-Hydroperoxycyclophosphamide; vol. 315; Jul. 17, 1986, No. 3; pp. 142-147.
Buddy Ullman, et al.; Specific Cytotoxicity of Arabinosylguanine Toward Cultured T. Lymphoblasts; vol. 74; Sep. 1984; pp. 951 955. *
Buddy Ullman, et al.; Specific Cytotoxicity of Arabinosylguanine Toward Cultured T. Lymphoblasts; vol. 74; Sep. 1984; pp. 951-955.
Cohen, et al., Selective Toxicity of Deoxyguanosine and Arabinosyl Guanine for T Leukiemic Cells, Blood, vol. 61, No. 4, Apr. 1983, pp. 660 666. *
Cohen, et al., Selective Toxicity of Deoxyguanosine and Arabinosyl Guanine for T-Leukiemic Cells, Blood, vol. 61, No. 4, Apr. 1983, pp. 660-666.
Donna S. Schewach, et al.; Metabolism and Selective Cyctotoxicity of 9 D Arabinofuranosyljuanine in Hyman Lymphoblasts; Cancer Research, vol. 45; Mar. 1985; pp. 1008 1014. *
Donna S. Schewach, et al.; Metabolism and Selective Cyctotoxicity of 9-D-Arabinofuranosyljuanine in Hyman Lymphoblasts; Cancer Research, vol. 45; Mar. 1985; pp. 1008-1014.
European Search Report. *
G. W. Santos; The Johns Hopkins Onconology Center; Busulfan (BU) and Cyclophosphamide (CY) for Marrow Transplantation; Bone Marrow Transplant, Jan. 1989; 4 suppl. 236 9. *
G. W. Santos; The Johns Hopkins Onconology Center; Busulfan (BU) and Cyclophosphamide (CY) for Marrow Transplantation; Bone Marrow Transplant, Jan. 1989; 4 suppl. 236-9.
The Journal of Clinical Investigation. vol. 74, No. 3, Sep., 1984. * 


https://www.drugbank.ca/drugs/DB01280